Skip to main content
. 2022 Jul 27;8(2):e002280. doi: 10.1136/rmdopen-2022-002280

Figure 4.

Figure 4

Changes from baseline in ASDAS and BASFI over time. Dashed line: all patients randomised to placebo in period 1 who received open-label upadacitinib starting from week 14. AO, as observed; ASDAS, Ankylosing Spondylitis Disease Activity Scores; BASFI, Bath Ankylosing Spondylitis Functional Index; MMRM, mixed-effect model repeated measure; QD, once daily; W, week.